Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene RegulationGlobeNewsWire • 10/07/24
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's DiseaseGlobeNewsWire • 10/03/24
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label MaintenanceGlobeNewsWire • 10/03/24
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024GlobeNewsWire • 09/26/24
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse ModelGlobeNewsWire • 09/25/24
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 09/13/24
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to TradeZacks Investment Research • 09/12/24
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General MeetingGlobeNewsWire • 06/04/24
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)Accesswire • 02/13/24
Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global MarketAccesswire • 10/24/23
U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market MovingSeeking Alpha • 10/21/23
Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global MarketAccesswire • 10/20/23
Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext ParisAccesswire • 10/20/23
Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price RangeAccesswire • 10/18/23
Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq ListingAccesswire • 10/16/23